PALO ALTO, Calif., Aug. 21, 2019 /PRNewswire/ -- Varian (NYSE:
VAR) today announced it has successfully completed its asset
purchase of the Boston Scientific portfolio of drug-loadable
microsphere and bland embolic bead products for treating
arteriovenous malformations and hypervascular tumors. This
acquisition expands the portfolio of Varian interventional oncology
solutions. To view the original announcement from July 2, 2019, visit:
https://www.varian.com/news/varian-expand-interventional-oncology-portfolio-purchase-embolic-bead-asset.
About Varian
At Varian, we envision a world without fear of cancer. For more
than 70 years, we have developed, built and delivered innovative
cancer care technologies and solutions for our clinical partners
around the globe to help them treat millions of patients each year.
With an Intelligent Cancer Care approach, we are harnessing
advanced technologies like artificial intelligence, machine
learning and data analytics to enhance cancer treatment and expand
access to care. Our 9,200 employees across 70 countries keep the
patient and our clinical partners at the center of our thinking as
we power new victories in cancer care. Because, for cancer patients
everywhere, their fight is our fight. For more information, visit
http://www.varian.com and follow @VarianMedSys on Twitter.
Press Contact
Mark Plungy
Director, Global Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-completes-purchase-of-embolic-bead-asset-300905358.html
SOURCE Varian